Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06644924 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

A Phase 2 study of Asthma, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
118
Enrollment target
20
Study locations

NCT06644924 is a Phase 2 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 118 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06644924, a Phase 2 study of Asthma, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
118 participants
Enrollment target
20
Study locations

Study Summary

Phase II study, to investigate the therapeutic efficacy and safety of inhaled PT007 (referred to as AS MDI) compared with placebo MDI and open-label Ventolin Evohaler in male and female participants aged 18 to 65 years (inclusive) with asthma. This study consists of a screening/run-in period, a treatment period, and a follow-up phone call.

Conditions Studied

Asthma

Interventions

  • COMBINATION_PRODUCT Intervention: AS MDI
  • COMBINATION_PRODUCT Intervention: Ventolin Evohaler
  • COMBINATION_PRODUCT Intervention: Placebo matching AS MDI

Study Locations (20)

California

  • Research Site - Encinitas
  • Research Site - Lancaster
  • Research Site - Los Angeles
  • Research Site - Newport Beach
  • Research Site - San Diego
  • Research Site - San Jose
  • Research Site - Stockton

Florida

  • Research Site - Clearwater
  • Research Site - Miami
  • Research Site - Tallahassee
  • Research Site - Tampa

Missouri

  • Research Site - Columbia
  • Research Site - Saint Charles
  • Research Site - St Louis

Oregon

  • Research Site - Medford
  • Research Site - Portland

Texas

  • Research Site - Austin
  • Research Site - El Paso

Maryland

  • Research Site - White Marsh

North Carolina

  • Research Site - Raleigh

Trial Details

FieldValue
Enrollment Target 118 participants
Start Date 2025-02-10
Est. Completion 2025-06-04
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06644924

The ClinicalTrials.gov registry entry for NCT06644924 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (92% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Intervention: AS MDI is the first listed.

NCT06644924 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Missouri.

Frequently Asked Questions

What is clinical trial NCT06644924 about?

NCT06644924 is a clinical study titled "A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma". Phase II study, to investigate the therapeutic efficacy and safety of inhaled PT007 (referred to as AS MDI) compared with placebo MDI and open-label Ventolin Evohaler in male and female participants aged 18 to 65 years (inclusive) with asthma. This study consists of a screening/run-in period, a tre...

What is the current status of trial NCT06644924?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2025-02-10. Estimated completion is 2025-06-04.

What conditions does trial NCT06644924 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT06644924?

The interventions under investigation include: Intervention: AS MDI (COMBINATION_PRODUCT), Intervention: Ventolin Evohaler (COMBINATION_PRODUCT), Intervention: Placebo matching AS MDI (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06644924?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06644924 being conducted?

This trial has 20 study locations across California, Florida, Maryland, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.